Tamtam Try Tamtam free
Novonesis logo

Novonesis account plan

biological solutions for sustainability

At a glance

Novonesis is a Danish biosolutions company (enzymes, cultures, probiotics, HMOs) with EUR 4,157.6 million of 2025 sales and 11,641 employees.

Novonesis (legal entity Novozymes A/S, listed as NSIS B on Nasdaq Copenhagen) makes enzymes, cultures, probiotics, yeast, proteins and human milk oligosaccharides (HMOs) by industrial fermentation, sold to food, health, household care, agriculture and energy producers. It was formed by the combination of Novozymes and Chr. Hansen on January 29, 2024. In 2025 it reported net sales of EUR 4,157.6 million, 7% organic growth, an adjusted EBITDA margin of 37.1% and net profit of EUR 583.6 million, with 11,641 employees at end-2025 (5,104 in Denmark). Novo Holdings A/S holds 25.5% of the shares and 63.4% of the votes.

Business units

Strategic priorities

GROW strategy 2030 targets
Presented in August 2025, GROW targets 6-9% organic sales CAGR, an adjusted EBITDA margin of ~39% and adjusted ROIC excluding goodwill of ~16% by 2030.
Outgrowing end markets
Growth of the core comes from value-based pricing, penetration and sales synergies; pricing added close to 2 percentage points and synergies a good 1 point in 9M 2026.
Emerging markets presence
Emerging markets were 38% of 9M 2026 sales and are expected to grow faster than developed ones by 2030, helped by more local commercial presence and co-creation labs such as a detergent powder lab in India.
AI and data across R&D and operations
AlphaFold, Cradle models and quantum work with Kvantify are used in R&D; more than 600 AI ambassadors are to be trained, and the ERP system and data infrastructure are being upgraded.
Emissions reduction
The 2030 target is a 75% cut in scope 1 and 2 emissions from 2018; 67% had been achieved in 2025.

Latest results

In the first nine months of 2026, net sales reached EUR 3,375.6 million against EUR 3,161.0 million, with 7% organic growth (Q3: 6%). The adjusted EBITDA margin was 37.9%, 60 bps above 9M 2025, and net profit EUR 558.7 million. Food & Beverages grew 12% organically, while Human Health was flat on a weak North American probiotic supplements market. The 2026 outlook, raised in August from 5-7%, is confirmed at 7-8% organic growth with the adjusted EBITDA margin at the higher end of 37-38%.

Investments and deals

Feed Enzyme Alliance buyout
On June 2, 2025 it acquired dsm-firmenich's sales and distribution activities in the alliance for EUR 1,587.0 million, refinanced in March 2026 with EUR 1.7 billion of bonds rated A- by S&P.
Production capacity expansion
CAPEX is guided at the higher end of 12-14% of sales in 2026 for capacity expansion, up from 11.3% of sales in 2025.
Plumino Precision Fermentation (Thailand)
Acquired April 1, 2026 for EUR 41.3 million net of cash: a fermentation plant in Rayong with around 200 employees, to be expanded including for HMO production and expected to be commercially operational in 2027.
MicroBioGen
The remaining 77% of this Australian yeast-strain specialist was acquired October 1, 2026 for EUR 113.7 million in cash plus ~EUR 33 million deferred.
Share buyback
An inaugural EUR 1 billion multi-year buyback runs to end-2029, with EUR 75 million planned for 2026.

Challenges and risks

Cyber risk
A cyberattack causing material business disruption or data compromise is rated the higher-probability key risk.
Geopolitical and trade uncertainty
Tariffs, sanctions and supply disruptions are a key risk; US tariff refunds to customers had a minor negative effect on price in 2026.
North American probiotic supplements
Human Health was flat in 9M 2026 (Q3: -8%) on weakness in this market and customers' channel and product format shifts.
Country exits
Exiting Russia and Belarus and other countries cost around 1 percentage point of organic growth in 9M 2026.
Regulation built for chemicals
The CEO says biosolutions are still regulated under frameworks designed for traditional chemicals, which she calls a barrier to innovation.

What leadership says

“With strong sales and profitability, we continue to demonstrate the strength and resilience of Novonesis' diversified business... We remain confident in our full-year outlook, supported by a solid start to the fourth quarter.”

Ester Baiget, President and CEO · Novonesis Interim report 9M 2026, November 5, 2026

“We [represent] 1% to 5% of the cost of the products our customers produce, but we are a big enabler of the value they generate. This is why we are outgrowing all the markets we serve.”

Ester Baiget, President and CEO · IMD CEO Dialogue Series interview, October 7, 2025

“Now, we need a new framework that reflects today's science and solutions.”

Ester Baiget, President and CEO · IMD CEO Dialogue Series interview, October 7, 2025

“The worst thing you can do in an integration is to ever celebrate success.”

Ester Baiget, President and CEO · IMD CEO Dialogue Series interview, October 7, 2025

Where a supplier can help

Capacity expansion projects
CAPEX at the higher end of 12-14% of sales for capacity expansion, plus the Rayong plant expansion for HMO production, opens room for engineering, equipment and construction suppliers.
ERP and data infrastructure upgrade
The ongoing ERP and data infrastructure upgrade and the AI ambassador programme are entry points for IT, data and AI partners.
Cybersecurity
With cyberattack rated the higher-probability key risk, security and recovery providers can tie offers to the company's own risk ranking.
Local commercial presence in emerging markets
The goal of more local commercial presence in emerging markets supports partners in sales enablement, distribution and local application labs.
Integrating acquisitions
Folding in the Feed Enzyme Alliance, Plumino and MicroBioGen creates integration work in systems, supply chain and HR.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Novonesis?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Novonesis

What does Novonesis do?

Novonesis makes biosolutions (enzymes, cultures, probiotics, yeast, proteins and HMOs) by industrial fermentation for food, health, household care, agriculture and energy customers. It was formed by the combination of Novozymes and Chr. Hansen in January 2024.

What is Novonesis' revenue?

Net sales were EUR 4,157.6 million in 2025, with 7% organic growth. In the first nine months of 2026, net sales were EUR 3,375.6 million.

How many employees does Novonesis have?

Novonesis had 11,641 employees at the end of 2025, of which 5,104 in Denmark.

What is Novonesis' strategy?

The GROW strategy targets 6-9% organic sales CAGR and an adjusted EBITDA margin of ~39% by 2030, by growing the core, enhancing its position through innovation and scale, and accelerating the biosolutions market.

Who leads Novonesis?

Ester Baiget is President and CEO, Rainer Lehmann is CFO, and Cees de Jong chairs the board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)